Retatrutide vs AOD-9604: Triple Agonist vs Growth Hormone Fragment for Weight Loss
Retatrutide and AOD-9604 are both peptides being discussed for weight loss, but they are fundamentally different in mechanism, evidence quality, and regulatory status. Retatrutide is a triple receptor agonist (GLP-1, GIP, glucagon) currently in Phase 3 clinical trials with the highest weight loss ever reported for any anti-obesity drug. AOD-9604 is a growth hormone fragment that targets fat metabolism directly — but its largest clinical trial failed to show significant weight loss compared to placebo.
The recent RFK peptide reclassification announcement has renewed interest in AOD-9604 as it is expected to return to legal compounding status. This article compares the evidence for both peptides.
Side-by-Side Comparison
| Retatrutide | AOD-9604 | |
|---|---|---|
| Developer | Eli Lilly | Metabolic Pharmaceuticals (abandoned 2007) |
| Type | Triple receptor agonist (GLP-1/GIP/glucagon) | Growth hormone fragment (hGH 176-191) |
| Mechanism | Appetite suppression + increased energy expenditure | Fat breakdown (lipolysis) + blocks fat formation |
| Max weight loss | -28.7% at 68 weeks (TRIUMPH-4 Phase 3) | -2.8 kg at 12 weeks (best Phase 2 result) |
| Largest trial result | -28.7% body weight (n=445) | Not significant vs placebo (n=536) |
| Trial phase | Phase 3 (TRIUMPH program) | Phase 2b (failed; development stopped) |
| FDA status | Investigational new drug (NDA expected 2026) | Not FDA-approved; expected Category 1 reclassification |
| Administration | Once-weekly subcutaneous injection | Daily subcutaneous injection or oral |
| Appetite suppression | Yes (profound) | No |
| Prescription required | Clinical trial only (not yet approved) | Yes (compounding pharmacy, if reclassified) |
How the Mechanisms Differ
Retatrutide: Three Receptors, One Molecule
Retatrutide activates three receptor systems simultaneously:
- GLP-1 receptor — suppresses appetite through hypothalamic and brainstem signaling, slows gastric emptying
- GIP receptor — enhances insulin secretion and may improve fat metabolism
- Glucagon receptor — increases energy expenditure through thermogenesis and promotes hepatic fat oxidation
This means retatrutide reduces caloric intake (appetite suppression) and increases caloric expenditure (glucagon-driven thermogenesis). For more on the mechanism, see How Does Retatrutide Work?.
AOD-9604: Targeted Fat Metabolism
AOD-9604 is a synthetic 16-amino acid peptide derived from the C-terminal region of human growth hormone (amino acids 176-191). It was designed to isolate the fat-burning effects of growth hormone without the broader hormonal side effects.
AOD-9604 works through two mechanisms:
- Stimulates lipolysis — activates beta-3 adrenergic receptors in adipose tissue, promoting breakdown of stored fat
- Inhibits lipogenesis — blocks enzymes involved in new fat formation
Critically, AOD-9604 does not suppress appetite, does not affect gastric emptying, does not alter blood sugar or insulin sensitivity, and does not elevate IGF-1 levels. It acts exclusively on fat tissue.
Why This Matters
The fundamental difference: retatrutide changes how much you eat and how much energy your body burns. AOD-9604 only changes how your body processes existing fat stores — without affecting hunger or metabolic rate at a systemic level.
Weight Loss Data
Retatrutide Clinical Results
| Trial | Phase | Participants | Duration | Max Weight Loss |
|---|---|---|---|---|
| TRIUMPH-4 | Phase 3 | 445 | 68 weeks | -28.7% (12 mg dose) |
| Phase 2 (NEJM) | Phase 2 | 338 | 48 weeks | -24.2% (12 mg dose) |
In the Phase 2 trial, over 90% of participants on the highest dose lost at least 10% of body weight, and approximately 75% lost at least 20%. These are the highest weight loss numbers ever recorded for any anti-obesity drug in clinical trials.
AOD-9604 Clinical Results
| Trial | Phase | Participants | Duration | Result |
|---|---|---|---|---|
| Phase 2b (Australia) | Phase 2b | 300 | 12 weeks | -2.8 kg (1 mg dose) vs -0.8 kg placebo |
| OPTIONS Study | Phase 2b | 536 | 24 weeks | -2.6 kg vs -2.3 kg placebo (NOT significant) |
| Pilot study | Phase 1/2 | 15 | 12 weeks | -1.8 kg vs -0.8 kg placebo |
The first Phase 2b trial (n=300) showed modest weight loss of 2.8 kg at the 1 mg oral dose over 12 weeks, with the lowest dose performing best — an unusual inverse dose-response pattern that raised questions.
The larger OPTIONS study (n=536, 24 weeks) was designed to confirm these results. It failed its primary efficacy endpoint — the 0.3 kg difference between AOD-9604 and placebo was not statistically significant. Development was abandoned in February 2007, and no Phase 3 trial was ever conducted.
The Evidence Gap
To put the numbers in perspective:
- Retatrutide produced approximately 24-29 kg of weight loss in average participants over 48-68 weeks
- AOD-9604 produced, at best, 2.0 kg more than placebo over 12 weeks — and its larger trial showed no significant benefit at all
This is not a matter of degree. Retatrutide has Level 1 evidence (large randomized controlled trials published in the New England Journal of Medicine). AOD-9604 has a failed Phase 2b trial and abandoned development.
Safety Comparison
| Retatrutide | AOD-9604 | |
|---|---|---|
| Common side effects | Nausea, diarrhea, constipation, vomiting | Mild injection-site reactions, headache |
| GI effects | Consistent with GLP-1 class (dose-related) | Minimal |
| Unique signal | Dysesthesia (tingling) in 8.8-20.9% | None identified |
| Blood sugar impact | Improves glucose control | No effect |
| IGF-1 impact | Not applicable | No effect (unlike full GH) |
| Safety database | ~5,800 participants across TRIUMPH program | ~925 participants across 6 trials |
| Discontinuation rate | 12-18% (TRIUMPH-4) | Not reported (no safety-related withdrawals) |
AOD-9604 has a favorable safety profile — a 2013 meta-analysis of six trials (n=900+) found it "indistinguishable from placebo" in terms of adverse events, with no effect on glucose metabolism, IGF-1, or immune response. It received FDA GRAS (Generally Recognized As Safe) status as a food additive for the oral form.
However, this safety advantage is largely because AOD-9604 has minimal biological activity at the doses tested. A drug that produces no meaningful weight loss compared to placebo is unlikely to produce significant side effects either.
Retatrutide has typical GLP-1 class side effects (primarily GI-related during dose escalation) plus a unique dysesthesia signal likely related to the glucagon receptor. For full details, see Retatrutide Side Effects & Safety.
Regulatory and Access Comparison
| Retatrutide | AOD-9604 | |
|---|---|---|
| FDA approval | NDA expected 2026; approval possible 2027 | Not FDA-approved for any indication |
| Current access | Clinical trials only (TRIUMPH program) | Gray market; expected to return to compounding pharmacies |
| Prescription pathway | Will require prescription once approved | Compounding pharmacy with prescription (if reclassified) |
| Insurance coverage | Expected once approved | No insurance coverage |
| Estimated cost | $349-499/month (projected, via LillyDirect) | $50-150/month (compounding pharmacy) |
| Quality control | Pharmaceutical-grade (cGMP manufacturing) | Varies by compounding pharmacy |
AOD-9604 is expected to be among the 14 peptides reclassified from Category 2 (banned) to Category 1 (legal to compound) under the RFK peptide reclassification. If this happens, licensed compounding pharmacies would be able to prepare AOD-9604 with a valid prescription from a healthcare provider.
Retatrutide is an investigational drug that cannot be compounded or purchased legally outside of clinical trials. For current access options, see Retatrutide Cost & How to Get It.
Can You Combine AOD-9604 With Retatrutide?
Some clinics and online communities discuss "stacking" AOD-9604 with GLP-1 drugs for a combined fat metabolism and appetite suppression approach. There is a theoretical rationale — they target completely different pathways — but no clinical trial has studied this combination.
The risks of combining them include:
- No safety data exists for the combination
- AOD-9604's own efficacy data is weak
- Adding an unproven compound to a potent drug introduces unknown variables
- Retatrutide is not available outside of clinical trials, so anyone combining them is using gray market products
Frequently Asked Questions
Is AOD-9604 better than retatrutide for weight loss?
No. The clinical evidence strongly favors retatrutide. Retatrutide produced 24-29% body weight loss in trials. AOD-9604's largest trial (n=536) failed to show significant weight loss compared to placebo. The evidence gap is categorical, not a matter of degree.
Why is AOD-9604 popular if it failed clinical trials?
AOD-9604 is popular because it is cheaper, easier to access (through compounding pharmacies and gray market vendors), has a favorable safety profile, and is marketed by wellness clinics. It is often positioned as a complement to GLP-1 drugs rather than a replacement, targeting "stubborn fat" that appetite-suppressing drugs may not address. However, the marketing claims are not supported by clinical trial evidence.
Is AOD-9604 legal?
As of March 2026, AOD-9604 is in regulatory limbo. It was removed from the FDA's Category 2 (banned) list in September 2024 and referred to the Pharmacy Compounding Advisory Committee. HHS Secretary RFK Jr. has announced that approximately 14 peptides, likely including AOD-9604, will be reclassified to Category 1 (legal to compound). This formal reclassification has not yet been published. See Are Peptides Legal in 2026? for the full regulatory picture.
Does AOD-9604 work for fat loss?
AOD-9604 has a plausible mechanism for fat metabolism (lipolysis stimulation, lipogenesis inhibition), and animal studies showed significant fat reduction. However, the two human trials showed conflicting results. The smaller trial (n=300) showed modest fat loss at the lowest dose. The larger trial (n=536) failed to show any significant benefit over placebo. Development was abandoned in 2007.
Can you take AOD-9604 while waiting for retatrutide?
This is a question for your healthcare provider. AOD-9604 targets a completely different mechanism than GLP-1 drugs and would not provide comparable weight loss results. If you are looking for weight loss medication while waiting for retatrutide, FDA-approved GLP-1 drugs like tirzepatide (Zepbound) or semaglutide (Wegovy) have far stronger evidence. See current GLP-1 pricing.
What is the difference between AOD-9604 and GLP-1 drugs?
They work through completely different mechanisms. GLP-1 drugs (semaglutide, tirzepatide, retatrutide) primarily suppress appetite through brain signaling and slow gastric emptying. AOD-9604 directly targets fat cells to promote fat breakdown and block fat formation — but does not affect appetite, hunger, or food intake at all. GLP-1 drugs have extensive Phase 3 clinical evidence. AOD-9604 failed its only large clinical trial.
Sources
- Jørgensen, J.O.L., et al. (2004). Phase 2b trial of oral AOD-9604 in obese subjects. Metabolic Pharmaceuticals press release, December 2004.
- Metabolic Pharmaceuticals. (2007). OPTIONS Study results. The Age, Feb 21, 2007.
- Stier, H., Vos, E., Kenley, D. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 3(1-2):7-15.
- Heffernan, M.A., et al. (2001). Effects of hGH and AOD9604 on lipid metabolism in obese mice. Endocrinology. PMID: 11713213.
- Jastreboff, A.M., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972.
- Eli Lilly. (2025). TRIUMPH-4 results. Press release.
Medical Disclaimer
The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug not yet approved by the FDA. AOD-9604 is not FDA-approved for any therapeutic indication.
Do not use this information to make decisions about your health without consulting a qualified healthcare provider. If you are considering weight loss medication, talk to your doctor about currently approved options.
This site is not affiliated with Eli Lilly, Metabolic Pharmaceuticals, or any pharmaceutical manufacturer.
Sources
- Retatrutide Phase 2 trial (NEJM)
New England Journal of Medicine
- AOD-9604 mechanism study
PubMed
Related reading
Peptides for Weight Loss vs GLP-1 Drugs: What the Evidence Says
GLP-1 drugs have Phase 3 trials and FDA approval. Research peptides have failed trials and animal data. The full evidence comparison.
Are Peptides Legal in 2026? The FDA Reclassification Explained
RFK announced 14 banned peptides returning to legal compounding. What it means, which peptides, and how it affects weight loss drugs.
Retatrutide Cost & How to Get It
What retatrutide might cost, how to access it through clinical trials, and why gray market peptides are dangerous.